Generics and biosimilars

Statistics report about generic drugs and biosimilars

Generics and biosimilars

This report presents graphs and tables about the global generic drug industry and market. It also includes a chapter about biosimilars, complex, almost identical copies of biological drugs, which like generic drugs, have the potential for significant drug spending reductions.

Table of contents

Global overview

4
  • Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
  • Basic Statistic Worldwide generic prescription drug sales 2012-2026
  • Basic Statistic Global generic prescription drug revenues as share of prescribed revenue 2012-2026
  • Premium Statistic Patent expiration risks for total worldwide prescription drug revenue 2023-2028

Top companies

4
  • Premium Statistic Revenues of leading global generics manufacturers 2022
  • Premium Statistic Teva Pharmaceutical Industries' generic revenues by region 2016-2023
  • Premium Statistic Novartis revenue 2014-2023 by segment
  • Basic Statistic Pfizer's revenue by segment 2017-2019

U.S. market

6
  • Premium Statistic Brand and generic prescription medication spending in the U.S. 2006-2021
  • Premium Statistic U.S. brand and generic prescription drug spending 2017-2021
  • Basic Statistic Spending change on branded and generic medicines in the U.S. 2014-2021
  • Premium Statistic Unbranded generics revenue top corporations in U.S. 2017-2018
  • Premium Statistic Unbranded generics market share top corporations in U.S. 2017-2018
  • Premium Statistic Top pharma products by prescriptions U.S. 2021

Patent expiration

6
  • Premium Statistic Projected sales at risk due to patent expiry 2014-2023
  • Premium Statistic Top pharma companies by sales loss due to patent loss until 2018
  • Premium Statistic Forecast of new brand and LOE impact in developed pharma markets 2019-2026
  • Premium Statistic Top branded biologic drugs in the U.S. that will go generic by 2028
  • Premium Statistic Time from brand drug launch to generic patent challenges U.S. 1995-2014
  • Basic Statistic Comparison of pre-expiry and generic price for drugs U.S. 2015

Savings

7
  • Premium Statistic Savings through generic drug usage in the U.S. 2008-2022
  • Premium Statistic Total savings of top generic drugs in U.S. 2022
  • Premium Statistic Saving of U.S. costs through generic pharmaceuticals by condition 2022
  • Basic Statistic Savings through generic drug usage in the U.S., by age group 2022
  • Basic Statistic Savings through generic drug usage in the U.S., by payer 2022
  • Basic Statistic Percentage savings through generic drug usage in the U.S. by payer 2022
  • Basic Statistic Savings through generic drug usage in the U.S., by age group share 2022

Biosimilars

7
  • Premium Statistic Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
  • Premium Statistic Country-wise biosimilar pipelines number in development worldwide 2017
  • Premium Statistic Reduction in U.S. direct spending on originator biologics as of 2018
  • Premium Statistic Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2018
  • Premium Statistic Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
  • Premium Statistic Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
  • Basic Statistic Physician office payment for biosimilars in Medicare Part B 2022

Statista report shop

Explore all Statista reports

We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)